Koren W, Koldanov R, Postnov I Y, Postnov Y V
Central Research Laboratory, Ministry of Public Health, Moscow, Russia.
Am J Hypertens. 1997 Mar;10(3):341-5. doi: 10.1016/s0895-7061(96)00394-9.
The study was undertaken to determine the possible effect of an aldosterone antagonist, spironolactone (SP), on red blood cell sodium-hydrogen exchange (NHE) enhancement in primary aldosteronism (PA) and essential hypertension (EH). NHE was measured as the amiloride-inhibited fraction of H+ efflux (V max) from erythrocytes (pHi 6.40 +/- 0.05) into a Na+-containing medium (pHo 8.00 +/- 0.05). Subjects were 12 hypertensive patients with aldosterone-producing adrenal adenoma (six treated with 200 mg/day spironolactone for an least 5 days and six drug-free), 20 essential hypertensives (10 treated with the same regimen of spironolactone and 10 drug-free), and 20 healthy controls. Treatment with spironolactone decreased NHE in PA patients but did not change the mean NHE in essential hypertensives. It is concluded that SP may be useful to differentiate between elevated NHE in PA and essential hypertension.
本研究旨在确定醛固酮拮抗剂螺内酯（SP）对原发性醛固酮增多症（PA）和原发性高血压（EH）患者红细胞钠氢交换（NHE）增强的可能影响。NHE的测定方法为，将红细胞（细胞内pH值6.40±0.05）置于含钠培养基（细胞外pH值8.00±0.05）中，测量氨氯地平抑制的氢离子外流（V max）部分。研究对象包括12例患有醛固酮分泌性肾上腺腺瘤的高血压患者（6例接受每日200 mg螺内酯治疗至少5天，6例未用药）、20例原发性高血压患者（10例接受相同螺内酯治疗方案，10例未用药）以及20例健康对照者。螺内酯治疗可降低PA患者的NHE，但对原发性高血压患者的平均NHE无影响。结论是，SP可能有助于区分PA和原发性高血压中升高的NHE。
